red.jpg
RedHill Biopharma Provides Update on Opaganib (Yeliva®)
11 mars 2020 07h00 HE | RedHill Biopharma Ltd.
      Phase 2 study evaluating RedHill’s proprietary NCE1 opaganib (Yeliva®, ABC294640) in prostate cancer initiated at Medical University of South Carolina, supported by an NCI grant --- ...
red.jpg
RedHill Biopharma Announces Advancement to Second Stage of Phase IIa Study with YELIVA® for Cholangiocarcinoma
06 sept. 2018 08h00 HE | RedHill Biopharma Ltd.
The first stage of the Phase IIa study with YELIVA® for advanced cholangiocarcinoma (bile duct cancer), a highly lethal malignancy, achieved its pre-specified efficacy goal, and the study can...
red.jpg
RedHill Biopharma Announces Peer-Reviewed Publication Demonstrating Therapeutic Potential of YELIVA™ in Cholangiocarcinoma Cancer
10 mars 2016 09h02 HE | RedHill Biopharma Ltd.
The article was authored by scientists from the Mayo Clinic Cancer Center, the Hollings Cancer Center at the Medical University of South Carolina and Apogee Biotechnology Corporation  RedHill...